Bruker (BRKR)

• Market cap: $7.7B
• 1 day: -3.97%
• 5 days: -1.32%
• 1 month: -15.40%
• 3 months: -9.61%
• 6 months: -21.88%
• Year to date: -13.59%
• 1 year: -37.96%
• 5 years: 2.50%
• 10 years: 166.35%
• Sector: Industrials
• Industry: Laboratory Analytical Instruments

About: Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.

Employees: 9,707

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

29% more repeat investments, than reductions

Existing positions increased: 144 | Existing positions reduced: 112

20% more funds holding in top 10

Funds holding in top 10: 5 [Q3] → 6 (+1) [Q4]

3.8% more ownership

Funds ownership: 76.95% [Q3] → 80.75% (+3.8%) [Q4]

5% more first-time investments, than exits

New positions opened: 65 | Existing positions closed: 62

1% less funds holding

Funds holding: 363 [Q3] → 358 (-5) [Q4]

10% less capital invested

Capital invested by funds: $7.95B [Q3] → $7.18B (-$770M) [Q4]

66% less call options, than puts

Call options by funds: $31.4M | Put options by funds: $91.6M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $57 12% upside
• Avg. target: $65 27% upside
• High target: $80 57% upside

5 analyst ratings

• positive: 2 40%
• neutral: 3 60%
• negative: 0 0%

Stifel Daniel Arias 37% 1-year accuracy 7 / 19 met price target	12% upside $57	Hold Maintained	14 Feb 2025
Barclays Luke Sergott 31% 1-year accuracy 16 / 52 met price target	18% upside $60	Overweight Maintained	14 Feb 2025
B of A Securities Derik De Bruin 45% 1-year accuracy 9 / 20 met price target	57% upside $80	Buy Maintained	13 Dec 2024
UBS Dan Leonard 43% 1-year accuracy 3 / 7 met price target	30% upside $66	Neutral Assumed	10 Dec 2024
Goldman Sachs Matthew Sykes 56% 1-year accuracy 22 / 39 met price target	18% upside $60	Neutral Upgraded	5 Dec 2024